DOXERCALCIFEROL injection, solution

Doxercalciferol by

Drug Labeling and Warnings

Doxercalciferol by is a Prescription medication manufactured, distributed, or labeled by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited (F3). Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    • Doxercalciferol Injection is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis
  • 2 DOSAGE AND ADMINISTRATION

    2.1 Prior to Initiation of Doxercalciferol Injection

     Ensure serum calcium is not above the upper limit of normal before initiating treatment with Doxercalciferol Injection [see Warnings and Precautions (5.1)]. 

    2.4 Important Administration Instructions for Doxercalciferol Injection

    • Administer Doxercalciferol Injection intravenously as a bolus dose at the end of dialysis.
    • Inspect Doxercalciferol Injection visually prior to administration; the solution should appear clear and colorless. Do not use if the solution is not clear or particles are present.
    • After initial vial use: 
           o discard unused portion of the single-dose vial;
           o store opened multiple-dose vial for up to 3 days at 2°C to 8°C (36°F to 46°F). Discard unused portion of multiple-dose vial after 3 days [see How Supplied/Storage and Handling (16)].

    2.5 Dosage Recommendations for Doxercalciferol Injection in Patients with CKD on Dialysis

    • Initiate Doxercalciferol Injection at a dose of 4 mcg given by bolus intravenous administration three times weekly at the end of dialysis (no more frequently than every other day).
    • Target the maintenance dose of Doxercalciferol Injection to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits.
    • Monitor serum calcium, phosphorus, and intact PTH levels weekly after initiation of therapy or dose adjustment.
    • Titrate the dose of Doxercalciferol Injection based on intact PTH. The dose may be increased at 8-week intervals by 1 mcg to 2 mcg if intact PTH is not lowered by 50% and fails to reach the target range. The maximum dose is 18 mcg weekly. Prior to raising the dose, ensure serum calcium is within normal limits
    • Suspend or decrease the dose if intact PTH is persistently and abnormally low to reduce the risk of adynamic bone disease [see Warnings and Precautions (5.4)] or if serum calcium is consistently above the normal range to reduce the risk of hypercalcemia [see Warnings and Precautions (5.1)]. If suspended, the drug should be restarted one week later at a dose that is at least 1 mcg lower.

    2.6 Drug Interactions that May Require Dosage Adjustments of Doxercalciferol Injection

    • Increased monitoring of serum calcium and dose adjustment of Doxercalciferol Injection may be necessary when given concomitantly with drugs that may increase the risk of hypercalcemia [see Drug Interactions (7)].
    • Increased monitoring of both serum calcium and intact PTH as well as dose adjustment of Doxercalciferol Injection may be necessary when given concomitantly with cytochrome P450 inhibitors or enzyme inducers [see Drug Interactions (7)].

  • 3 DOSAGE FORMS AND STRENGTHS


    Injection: clear and colorless solution available as follows:

    • 4 mcg/2 mL (2 mcg/mL) multiple-dose vial.

  • 4 CONTRAINDICATIONS


    Doxercalciferol Injection is contraindicated in patients with:

    • Hypercalcemia [see Warnings and Precautions (5.1)]
    • Vitamin D toxicity [see Warnings and Precautions (5.1)]
    • Known hypersensitivity to doxercalciferol or any of the inactive ingredients of Doxercalciferol Injection; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported [see Warnings and Precautions (5.3), Adverse Reactions (6.2)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypercalcemia

    Hypercalcemia may occur during Doxercalciferol Injection treatment. Acute hypercalcemia may increase the risk of cardiac arrhythmias and seizures and may potentiate the effect of digitalis on the heart [see Warnings and Precautions (5.2)]. Chronic hypercalcemia can lead to generalized vascular calcification and other soft-tissue calcification. Severe hypercalcemia may require emergency attention.


    Hypercalcemia may be exacerbated by concomitant administration of high doses of calcium-containing preparations, thiazide diuretics, or other vitamin D compounds [see Drug Interactions (7)]. In addition, high intake of calcium and phosphate concomitantly with vitamin D compounds may lead to hypercalciuria and hyperphosphatemia. Patients with a history of hypercalcemia prior to initiating therapy may be at increased risk for development of hypercalcemia with Doxercalciferol Injection. In these circumstances, frequent serum calcium monitoring and Doxercalciferol Injection dose adjustments may be required.


    When initiating Doxercalciferol Injection or adjusting Doxercalciferol Injection dose, measure serum calcium frequently (weekly in patients with CKD on dialysis or every 2 weeks for patients with stage 3 or 4 CKD). Once a maintenance dose has been established, measure serum calcium monthly for 3 months and then every 3 months. If hypercalcemia occurs, reduce the dose or discontinue Doxercalciferol Injection until serum calcium is normal [see Dosage and Administration (2)].


    Inform patients about the symptoms of elevated calcium (feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination and weight loss) and instruct them to report new or worsening symptoms when they occur.



    5.2 Digitalis Toxicity

    Doxercalciferol Injection can cause hypercalcemia [see Warnings and Precautions (5.1)] which increases the risk of digitalis toxicity. In patients using Doxercalciferol Injection concomitantly with digitalis compounds, monitor both serum calcium and patients for signs and symptoms of digitalis toxicity. Increase the frequency of monitoring when initiating or adjusting the dose of Doxercalciferol Injection [see Drug Interactions (7)].

    5.3 Serious Hypersensitivity Reactions

    Serious hypersensitivity reactions, including fatal outcome, have been reported post marketing in patients on hemodialysis following administration of Doxercalciferol Injection. Hypersensitivity reactions include anaphylaxis with symptoms of angioedema (involving face, lips, tongue and airways), hypotension, unresponsiveness, chest discomfort, shortness of breath, and cardiopulmonary arrest. These reactions may occur separately or together.


    Monitor patients receiving Doxercalciferol Injection upon initiation of treatment for hypersensitivity reactions. Should a hypersensitivity reaction occur, discontinue Doxercalciferol Injection, monitor and treat if indicated [see Contraindications (4)].

    5.4 Adynamic Bone Disease

    Adynamic bone disease with subsequent increased risk of fractures may develop if intact PTH levels are suppressed by Doxercalciferol Injection to abnormally low levels. Monitor intact PTH levels to avoid over suppression and adjust the Doxercalciferol Injection dose, if needed [see Dosage and Administration (2)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in greater detail in another section of the label:

    • Hypercalcemia [see Warnings and Precautions (5.1)]
    • Serious Hypersensitivity Reactions [see Warnings and Precautions (5.3)]
    • Adynamic Bone Disease [see Warnings and Precautions (5.4)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

     

    Adverse reactions in patients with CKD on dialysis

    Doxercalciferol capsules have been evaluated in two placebo-controlled, double-blind studies in patients with CKD on hemodialysis. Patients were treated with Doxercalciferol capsules (n=61) or placebo (n=61) [see Clinical Studies (14.2)]. After randomization to two groups, eligible patients underwent an 8-week washout period during which no vitamin D derivatives were administered to either group. Subsequently, all patients received Doxercalciferol capsules in an open-label fashion for 16 weeks followed by a double-blind period of 8 weeks during which patients received either Doxercalciferol capsules or placebo. Adverse reactions occurring in the Doxercalciferol capsule groups at a frequency of 2% or greater, and more frequently than in the placebo group are presented in Table 2.  


    Table 2: Adverse Reactions Occurring in ≥2% Doxercalciferol Capsule-Treated Patients with CKD on Dialysis and Greater than Placebo in Two Double-Blind Clinical Studies

     Adverse Reaction*
         		 Doxercalciferol (n=61) %
         		 Placebo (n=61) %
     
     Edema
         		 34
         		 21
     
     Malaise
         		 28
         		 20
     
     Headache
         		 28
         		 18
     
     Nausea/Vomiting
         		 21
         		 20
     
     Dizziness
         		 12
         		 10
     
     Dyspnea
         		 12
         		 7
     
     Pruritus
         		 8
         		 7
     
     Bradycardia
         		 7
         		 5
     
     Anorexia
         		 5
         		 3
     
     Dyspepsia
         		 5
         		 2
     
     Arthralgia
         		 5
         		 0
     
     Weight increase
         		 5
         		 0
     
     Abscess
         		 3
         		 0
     
     Sleep disorder
         		 3
         		 0
     

    * A patient who reported the same medical term more than once was counted only once for that medical term.


    Doxercalciferol Injection

    Adverse reactions in patients with CKD on hemodialysis.


    Doxercalciferol Injection has been studied in 70 patients with CKD on hemodialysis in two 12-week, open-label, single-arm, multicentre studies [see Clinical Studies (14.3)]. The incidence of hypercalcemia and hyperphosphatemia increased during therapy with Doxercalciferol Injection. Patients with higher pre-treatment serum levels of calcium (>10.5 mg/dL) or phosphorus (>6.9 mg/dL) were more likely to experience hypercalcemia or hyperphosphatemia.


    There was no placebo group included in the studies of Doxercalciferol Injection. Adverse reactions in patients with CKD on hemodialysis receiving Doxercalciferol Injection are expected to be similar to those reported in placebo-controlled studies of Doxercalciferol capsule presented in Table 2.



    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post approval use of Doxercalciferol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.


    Hypersensitivity reactions, including fatal outcome, have been reported in patients on hemodialysis following administration of Doxercalciferol Injection. Hypersensitivity reactions include anaphylaxis with symptoms of angioedema (involving face, lips, tongue and airways), hypotension, unresponsiveness, chest discomfort, shortness of breath, cardiopulmonary arrest, pruritus, and skin burning sensation.

  • 7 DRUG INTERACTIONS

    Tables 3 include clinically significant drug interactions with Doxercalciferol.


    Table 3: Clinically Significant Drug Interactions with Doxercalciferol Injection and Doxercalciferol Capsules.

     Drugs that May Increase the Risk of Hypercalcemia
     
     Clinical
     Impact
         		 Concomitant administration of high doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia. Thiazide diuretics are known to induce hypercalcemia by reducing excretion of calcium in the urine.
     
     Examples
         		 Calcium-containing products, other vitamin D compounds or thiazide diuretics
     
     Intervention
         		 Monitor serum calcium concentrations more frequently and adjust Doxercalciferol dose as needed [see Warnings and Precautions (5.1)].
     
     Digitalis Compounds
     
     Clinical
     Impact
         		 Doxercalciferol can cause hypercalcemia which can potentiate the risk of digitalis toxicity.
     
     Intervention
         		 Monitor patients for signs and symptoms of digitalis toxicity and increase frequency of serum calcium monitoring when initiating or adjusting the dose of Doxercalciferol in patients receiving digitalis compounds [see Warnings and Precautions (5.2)].
     
     Cytochrome P450 Inhibitors
     
     Clinical
     Impact
         		 Doxercalciferol is activated by CYP 27 in the liver. Cytochrome P450 inhibitors may inhibit the 25-hydroxylation of doxercalciferol and thus reduce the formation of active doxercalciferol moiety [see Clinical Pharmacology (12.3)].
     
     Examples
         		 Ketoconazole and erythromycin
     
     Intervention
         		 If a patient initiates or discontinues therapy with a cytochrome P450 inhibitor, dose adjustment of Doxercalciferol may be necessary. Monitor intact PTH and serum calcium concentrations closely.
     
     Enzyme Inducers
     
     Clinical
     Impact
         		 Doxercalciferol is activated by CYP 27 in the liver. Enzyme inducers may affect the 25-hydroxylation of doxercalciferol [see Clinical Pharmacology (12.3)].
     
     Examples
         		 Glutethimide and phenobarbital
     
     Intervention
         		 If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of Doxercalciferol may be necessary. Monitor intact PTH and serum calcium concentrations closely.
     
     Magnesium-containing Products
     
     Clinical
     Impact
         		 Concomitant administration of Doxercalciferol and high doses of magnesium-containing products may increase the risk of hypermagnesemia.
     
     Examples
         		 Magnesium-containing products such as antacids
     
     Intervention
         		 Avoid use of magnesium-containing products and Doxercalciferol in patients on chronic renal dialysis.
     
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy


    Risk Summary
    The limited available data with Doxercalciferol Injection in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see Clinical Considerations]. In reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/day, respectively (approximately 25 times (rats) and less than (rabbits) the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area), no adverse developmental effects were observed [see Data].

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    Clinical Considerations

    Disease-associated maternal and/or embryo/fetal risk


    Chronic kidney disease in pregnancy increases the risk for maternal hypertension and preeclampsia, miscarriage, preterm delivery polyhydramnios, stillbirth, and low-birth-weight infants.



    Data
    Animal data
    There were no adverse effects on fetal development when doxercalciferol was administered at doses up to 20 mcg/kg/day in pregnant rats or doses up to 0.1 mcg/kg/day in pregnant rabbits during the period of organogenesis.


    8.2 Lactation

    Risk Summary

    There is no information available on the presence of doxercalciferol in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Infants exposed to Doxercalciferol Injection through breast milk should be monitored for signs and symptoms of hypercalcemia [see Clinical Considerations].

     

    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Doxercalciferol Injection and any potential adverse effects on the breastfed child from Doxercalciferol Injection or from the underlying maternal condition.


    Clinical Considerations

    Infants exposed to Doxercalciferol Injection through breast milk should be monitored for signs and symptoms of hypercalcemia, including seizures, vomiting, constipation and weight loss. Monitoring of serum calcium in the infant should be considered.

    8.4 Pediatric Use

    Safety and efficacy of Doxercalciferol Injection in pediatric patients have not been established.

    8.5 Geriatric Use

    Clinical studies of Doxercalciferol Injection did not include sufficient numbers of patients 65 years or over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy.


    8.6 Hepatic Impairment

    Patients with hepatic impairment may not metabolize Doxercalciferol Injection appropriately. More frequent monitoring of intact PTH, calcium, and phosphorus levels should be done in patients with hepatic impairment.

  • 10 OVERDOSAGE

    Overdosage of Doxercalciferol Injection may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia [see Warnings and Precautions (5.1)]. The treatment of acute overdosage should consist of supportive measures and discontinuation of Doxercalciferol Injection administration. Serum calcium levels should be measured until normal.
    Based on similarities between doxercalciferol and its active metabolite, 1α,25-(OH)2D2, it is expected that doxercalciferol is not removed from the blood by dialysis.

  • 11 DESCRIPTION


    Doxercalciferol injection contains doxercalciferol, which is a synthetic vitamin D2 analog. Doxercalciferol undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2.

    Doxercalciferol is a white to off-white crystallized powder with a calculated molecular weight of 412.66 and a molecular formula of C28H44O2. It is soluble in oils and organic solvents, but is relatively insoluble in water. Chemically, doxercalciferol is (1α,3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol. The structural formula is:

    doxercalciferol-structure




    Injection

    Doxercalciferol Injection is a sterile, clear, and colorless solution.


    Doxercalciferol Injection 2 mL multiple-dose vials contain 4 mcg/2 mL (2 mcg/mL) of doxercalciferol. Each milliliter (mL) of solution contains 2 mcg doxercalciferol and the following inactive ingredients: butylated hydroxytoluene (0.02 mg); disodium edetate (1.1 mg); dehydrated alcohol (7.5% v/v); polysorbate 20 (10 mg); sodium chloride (1.5 mg); dibasic sodium phosphate, heptahydrate (14.4 mg); and monobasic sodium phosphate, monohydrate (1.8 mg).


  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Doxercalciferol is a synthetic vitamin D2 analog that requires metabolic activation to form the active 1α,25-(OH)2D2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways. Vitamin D and doxercalciferol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.

    12.3 Pharmacokinetics


    Absorption
    In healthy volunteers, peak blood levels of 1α,25-(OH)2D2, the major metabolite of doxercalciferol, are attained at 8 hours after a single intravenous dose of Doxercalciferol Injection.

    Elimination
    The mean elimination half-life of 1α,25-(OH)2D2 after an oral dose is approximately 32 to 37 hours with a range of up to 96 hours.
     
    Metabolism
    Doxercalciferol is activated by CYP 27 in the liver to form 1α,25-(OH)2D2 (major metabolite) and 1α,24- dihydroxyvitamin D2 (minor metabolite). Activation of doxercalciferol does not require the involvement of the kidneys.
     
    Specific Populations
    Patients with renal impairment
    The mean elimination half-life of 1α,25-(OH)2D2 in patients with end-stage renal disease (ESRD) and in healthy volunteers appears to be similar following an oral dose. Hemodialysis causes a temporary increase in 1α,25- (OH)2D2 mean concentrations, presumably due to volume contraction. 1α,25-(OH)2D2 is not removed from blood during hemodialysis.


  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


    In a 104-week carcinogenicity study in rats, there was an increased incidence of benign and malignant adrenal pheochromocytomas in both males and females at oral doses of 0.04, 0.13, and 0.39 mcg/kg/day (less than the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area). This increased incidence of pheochromocytomas in rats may be due to altered calcium homeostasis by doxercalciferol. No evidence of genetic toxicity was observed in an in vitro bacterial mutagenicity assay (Ames test) or a mouse lymphoma gene mutation assay. Doxercalciferol caused structural chromatid and chromosome aberrations in an in vitro human lymphocyte clastogenicity assay with metabolic activation. However, doxercalciferol was negative in an in vivo mouse micronucleus clastogenicity assay.

    Doxercalciferol had no effect on male or female fertility in rats at oral doses up to 2.5 mcg/kg/day (approximately 3 times the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area).


  • 14 CLINICAL STUDIES

    14.3 Clinical Studies of Doxercalciferol Injection in Patients with CKD on Dialysis


    The safety and effectiveness of Doxercalciferol injection were evaluated in two open-label, single-arm, multicentre clinical studies (Study C and Study D) in a total of 70 patients with CKD on hemodialysis. Patients in Study C were an average age of 54 years (range: 23 to 73), were 50% male, and were 61% African-American, 25% Caucasian, and 14% Hispanic, and had been on hemodialysis for an average of 65 months. 


    Patients in Study D were an average age of 51 years (range: 28 to 76), were 48% male, and 100% African- American and had been on hemodialysis for an average of 61 months. This group of 70 of the 138 patients who had been treated with Doxercalciferol capsules in prior clinical studies received Doxercalciferol Injection in an open-label fashion for 12 weeks following an 8-week washout (control) period. 


    Dosing of Doxercalciferol Injection was initiated at the rate of 4 mcg administered at the end of each dialysis session (3 times weekly) for a total of 12 mcg per week. The dosage of Doxercalciferol Injection was adjusted to achieve intact PTH levels (measured weekly) within a targeted range of 150 pg/mL to 300 pg/mL. The dosage was increased by 2 mcg per dialysis session after 8 weeks of treatment if the intact PTH levels remained above 300 pg/mL and were greater than 50% of baseline levels. The maximum dosage was limited to 18 mcg per week. If at any time during the study intact PTH fell below 150 pg/mL, Doxercalciferol Injection was immediately suspended and restarted at a lower dosage the following week. Mean weekly doses ranged from 9 mcg to 13 mcg in Study C and ranged from 9 mcg to 12 mcg in Study D.


    Fifty-two (74%) of the 70 patients who were treated with Doxercalciferol Injection achieved intact PTH levels ≤300 pg/mL. Forty-one (59%) of these patients exhibited plasma intact PTH levels ≤300 pg/mL on at least 3 occasions. Thirty-six (51%) patients had plasma intact PTH levels <150 pg/mL on at least one occasion during study participation. Decreases in plasma intact PTH from baseline values were calculated using as baseline the average of the last 3 values obtained during the 8-week washout period and are displayed in Table 6.



    Table 6: Intact PTH Summary Data for Patients with CKD on Dialysis Receiving Doxercalciferol Injection in Studies C and D

     

     Intact PTH Level
         		 Study C (n=28)
         		 Study D (n=42)
         		 Combined Protocols (n=70)
     
     Baseline (Mean of Weeks -2, -1, and 0)
     
     Mean (SE)
         		 698 (60)
         		 762 (65)
         		 736 (46)
     
     Median
         		 562
         		 648
         		 634
     
     On-treatment (Week 12*)
     
     Mean (SE)
         		 406 (63)
         		 426 (60)
         		 418 (43)
     
     Median
         		 311
         		 292
         		 292
     
     Change from Baseline†
     
     Mean (SE)
         		 -292 (55)
         		 -336 (41)
         		 -318 (33)
     
     Median
         		 -274
         		 -315
         		 -304
     
     P-value‡
         		 0.004
         		 0.001
         		 <0.001
     

    * Values were carried forward for the two patients on study for 10 weeks
    † Treatment intact PTH minus baseline intact PTH
    ‡ Wilcoxon one-sample test

    Doxercalciferol Injection treatment resulted in at least 30% reduction from baseline in mean intact PTH levels during the 12-week open-label treatment period in more than 92% of the 70 treated patients.


  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

     

    Doxercalciferol injection is a clear, colorless solution supplied in 2 mL amber glass vials as follows.


     Total Strength
     Per Total Volume
         		 Strength
     per mL
         		 Flip-off
     Cap Color
         		 Vial Count per Carton × Total Vial Volume and Vial Type
         		 Carton NDC
         		 Vial NDC
     
     4 mcg/2 mL
         		 2 mcg/mL
         		 Light green
         		 25 ×  1 vial (2 mL multiple-dose vial)
         		 62332-690-50
         		 62332-690-02
     
     50 ×  1 vial (2 mL multiple-dose vial)
         		 62332-690-30
         		 62332-690-02
     

    STORAGE AND HANDLING:

     Dosage Form
         		 Storage temperature
         		 Excursions permitted to
         		 In-use storage
     
     Multiple-dose vial*
         		 25°C (77°F)
         		 15°C to 30°C (59°F to 86°F)
     [see USP controlled room temperature]
         		 2°C to 8°C (36°F to 46°F), Discard 3 days after opening
     

    *Protect from light. Store unopened vial in original carton.

  • 17 PATIENT COUNSELING INFORMATION

    Hypercalcemia
    Advise patients to contact a health care provider if they develop symptoms of elevated calcium (e.g. feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination and weight loss) [see Warnings and Precautions (5.1)].


    Hypersensitivity
    Inform patients that hypersensitivity reactions can occur with Doxercalciferol Injection [see Warnings and Precautions (5.3)].


    Monitoring
    Inform patients that they will need routine monitoring of laboratory parameters such as calcium and intact PTH while receiving doxercalciferol. Inform patients that more frequent monitoring is necessary during the initiation of therapy, following dose changes or when potentially interacting medications are started or discontinued [see Dosage and Administration (2), Drug Interactions (7)].


    Drug Interactions
    Advise patients to inform their physician of all medications, including prescription and nonprescription drugs, and supplements they are taking. Advise patients to also inform their physician that they are receiving Doxercalciferol Injection if a new medication is prescribed [see Drug Interactions (7)].


    Rx Only


    Manufactured for:
    Alembic Pharmaceuticals, Inc.
    Bedminster, NJ 07921, USA


    Made in India.


    Manufactured by:
    Alembic Pharmaceuticals Limited
    Karakhadi 391450, Gujarat, India


    Issued: 03/2023

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL)-Container Label:

     doxer-vial 

    Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL)-Carton Label (25's Pack):

    doxercalciferol-carton-25-2


    Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL)-Carton Label (50's Pack):

    doxercalciferol-carton-50 

  • INGREDIENTS AND APPEARANCE
    DOXERCALCIFEROL 
    doxercalciferol injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-690
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DOXERCALCIFEROL (UNII: 3DIZ9LF5Y9) (DOXERCALCIFEROL - UNII:3DIZ9LF5Y9) DOXERCALCIFEROL4 ug  in 2 mL
    Inactive Ingredients
    Ingredient NameStrength
    POLYSORBATE 20 (UNII: 7T1F30V5YH)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)  
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    ALCOHOL (UNII: 3K9958V90M)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-690-5025 in 1 CARTON06/15/2023
    1NDC: 62332-690-022 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product
    2NDC: 62332-690-3050 in 1 CARTON06/15/2023
    2NDC: 62332-690-022 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21581006/15/2023
    Labeler - Alembic Pharmaceuticals Inc. (079288842)
    Establishment
    NameAddressID/FEIBusiness Operations
    Alembic Pharmaceuticals Limited (F3)675480734MANUFACTURE(62332-690)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.